HADLIMA

Approval Id: 9d70bb5c1bfdd0e1
Drug Approval Canada Name: HADLIMA
Product Name: HADLIMA
Status: Marketed
Status Date: 2023-10-25
Original Market Date: 2023-10-25
Din: 02533472
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Subcutaneous
Schedule: Schedule D , Prescription
Ahfs: 90:24.16.92
Atc Original: L04AB04 ADALIMUMAB
Atc Name: l 04 ab 04
Aig Number: 0150364002
Company Name: Samsung Bioepis Co., Ltd.
Company Address: 76, Songdogyoyuk-Ro, Yeonsu-Gu, Incheon, Incheon, Korea, Republic Of, 21987
Company Detail Path: /organization/samsung-bioepis-co-ltd

ADALIMUMAB

40 MG / 0.4 ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

9d70bb5c1bfdd0e1

Type

Standard